Clinical tests of a new tablet from a carcinoma cutaneum while yield rather impressing results. This medicine slows down tumour growth at a malignant melanoma in a finishing stage.
Almost at 80 % of the patients who have taken part in the first phase clinical tests in public of an experimental medicine for a malignant melanoma, considerable progress was observed. Their tumours have essentially decreased. Last night one of leading British experts in a carcinoma cutaneum named a new medicine "very promising".

Meanwhile the medicine is known under name PLX4032. The principle of its action consists that a preparation inhibits a "harmful" gene which constantly activates the fiber controlling division of malignant cells and growth of a tumour. During researches in America and Australia treatment by tablets PLX4032 was received by 48 patients at a finishing stage. At 37 tumours have considerably decreased, and in three cases in general have disappeared.

Now the modern oncology uses for therapy of an advanced carcinoma of a skin a medicine dacarbazine which is applied during chemotherapy. Its effect at melanoma treatment is rather low - a little appreciable effect is fixed only at 5-15 % of patients.

Malignant melanoma - the most dangerous form of the carcinoma cutaneum which reason of development is the excessive finding on the sun. This kind of a cancer has property to extend and on other organs. At timely diagnostics chances of full recover are rather great, but if illness has started to extend, forecasts happen are unfavourable.